A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy

Komal Umashankar Rao, Domhnall Iain Henderson, Nitya Krishnan, Manoj Puthia, Izabela Glegola-Madejska, Lena Brive, Fanny Bjarnemark, Anna Millqvist Fureby, Karin Hjort, Dan I. Andersson, Erik Tenland, Erik Sturegård, Brian D. Robertson, Gabriela Godaly

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review


Alternative ways to prevent and treat infectious diseases are needed. Previously, we identified a fungal peptide, NZX, that was comparable to rifampicin in lowering M. tuberculosis load in a murine tuberculosis (TB) infection model. Here we assessed the potential synergy between this cationic host defence peptide (CHDP) and the current TB drugs and analysed its pharmacokinetics. We found additive effect of this peptide with isoniazid and ethambutol and confirmed these results with ethambutol in a murine TB-model. In vivo, the peptide remained stable in circulation and preserved lung structure better than ethambutol alone. Antibiotic resistance studies did not induce mutants with reduced susceptibility to the peptide. We further observed that this peptide was effective against nontuberculous mycobacteria (NTM), such as M. avium and M. abscessus, and several Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. In conclusion, the presented data supports a role for this CHDP in the treatment of drug resistant organisms.

TidskriftScientific Reports
StatusPublished - 2021

Ämnesklassifikation (UKÄ)

  • Mikrobiologi inom det medicinska området
  • Farmaceutisk vetenskap


Utforska forskningsämnen för ”A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här